Riskpilot← Back to searchSign inGet full accessIncyte Biosciences Denmark ApS
APSActiveCVR 35818790Suomisvej 4Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20144 employees
Revenue 2024
DKK 7M
+12% vs 2023
EBITDA margin
6.7%
-2% vs 2023
Equity ratio
52.6%
Financial strength
Net profit 2024
DKK 369K
-2% vs 2023
| Revenue | DKK 7M | +12% |
| EBITDA | DKK 473K | -2% |
| Net profit | DKK 369K | -2% |
| Total assets | DKK 3,7M | -19% |
| Equity | DKK 2M | +23% |
| Employees | 4 | — |
Legal name
Incyte Biosciences Denmark ApS
CVR number
35818790
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. april 2014
Share capital
DKK 50.000
Employees
4 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af et bestyrelsesmedlem alene eller af en direktør alene.
Company purpose
Selskabets formål er at udbrede medicinsk og farmaceutisk viden og aktivitet, handel med medicinalvareprodukter samt enhver virksomhed som er beslægtet hermed.
Address
Suomisvej 4
Phone
+4520663890
Email
co.sec@incyte.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 602 | 1.532 | 1.495 | 2.043 | 3.031 | 4.830 | 5.397 | 5.288 | 5.557 | 6.283 | 7.046 |
| Staff expenses | -595 | -1.493 | -1.462 | -1.981 | -2.913 | -4.449 | -5.183 | -4.924 | -5.185 | -5.799 | -6.573 |
| EBITDA | 7 | 40 | 33 | 63 | 118 | 381 | 214 | 364 | 371 | 485 | 473 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 7 | 40 | 33 | 63 | 118 | 381 | 214 | 364 | 371 | 485 | 473 |
| Net financials | 0 | -5 | -2 | -2 | -6 | -15 | -15 | -18 | -17 | -1 | -8 |
| Profit before tax | 7 | 35 | 31 | 61 | 112 | 366 | 199 | 346 | 355 | 486 | 465 |
| Tax | 2 | 8 | 5 | 14 | 25 | 81 | 49 | 77 | 77 | 111 | 96 |
| Net profit | 5 | 26 | 25 | 47 | 87 | 286 | 150 | 269 | 278 | 375 | 369 |
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 475 | 987 | 995 | 1.825 | 1.307 | 2.424 | 3.371 | 3.442 | 6.991 | 4.603 | 3.740 |
| Equity | 55 | 82 | 107 | 154 | 241 | 527 | 677 | 946 | 1.224 | 1.598 | 1.967 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 419 | 905 | 888 | 1.671 | 1.066 | 1.897 | 2.694 | 2.496 | 5.767 | 3.005 | 1.772 |
| Total debt | 419 | 905 | 888 | 1.671 | 1.066 | 1.897 | 2.694 | 2.496 | 5.767 | 3.005 | 1.772 |
EBITDA margin
6.7%
This company
15.8%
Market median
-58% vs market
20142024
Equity ratio
52.6%
This company
38.2%
Market median
+38% vs market
20142024
Return on equity
18.7%
This company
18.4%
Market median
+2% vs market
20142024
Net profit margin
5.2%
This company
8.1%
Market median
-36% vs market
20142024
Asset turnover
1.88×
This company
1.12×
Market median
+68% vs market
20142024
Debt / equity
0.90×
This company
0.62×
Market median
+45% vs market
20142024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-04-01 – 2014-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
ET Management | Management | 2014 | — | — |
EG Management | Management | 2025 | — | — |
EC Management | Management | 2026 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2014 | — | — | |
| Chairman | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2017 | |
| Individual | 100.0% | 100.0% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Incyte Biosciences Denmark ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Thomas Fromm | Management | 0 companies |
| Erik Garardus Johannes Bokmans | Management | 0 companies |
| Ebba Cecilia Bröms | Management | 0 companies |
| Jonathan Elliot Dickinson | Chairman | 0 companies |
| Lee Jason Heeson | Chairman | 0 companies |